Matching articles for "PSA"
Safety of Testosterone Replacement Therapy
The Medical Letter on Drugs and Therapeutics • March 14, 2016; (Issue 1490)
Three coordinated double-blind, placebo-controlled
clinical trials have evaluated the efficacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in...
Three coordinated double-blind, placebo-controlled
clinical trials have evaluated the efficacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in a total of
790 men ≥65 years old with moderately low serum
testosterone concentrations and symptoms suggesting
hypoandrogenism. Sexual function improved
modestly, and there appeared to be marginal benefits
in some areas of physical function and vitality as well.
The trials were not designed to evaluate the safety of
testosterone replacement therapy.
Cancer Screening
The Medical Letter on Drugs and Therapeutics • December 1, 2012; (Issue 124)
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may
improve outcomes. Screening tests for some common
cancers are reviewed...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may
improve outcomes. Screening tests for some common
cancers are reviewed below.
PSA Reconsidered
The Medical Letter on Drugs and Therapeutics • August 6, 2012; (Issue 1396)
Three recent publications have focused attention once
more on the contentious question of whether men
should be screened for prostate cancer by measuring
serum concentrations of prostate specific antigen...
Three recent publications have focused attention once
more on the contentious question of whether men
should be screened for prostate cancer by measuring
serum concentrations of prostate specific antigen (PSA).
Dutasteride (Avodart) for Prevention of Prostate Cancer
The Medical Letter on Drugs and Therapeutics • April 19, 2010; (Issue 1336)
A study recently published in the New England Journal of Medicine concluded that dutasteride (Avodart –
GlaxoSmithKline), a 5α-reductase inhibitor marketed for treatment of symptomatic benign prostatic...
A study recently published in the New England Journal of Medicine concluded that dutasteride (Avodart –
GlaxoSmithKline), a 5α-reductase inhibitor marketed for treatment of symptomatic benign prostatic hyperplasia, reduced the risk of prostate cancer over a 4-year period.
Degarelix (Firmagon) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • October 19, 2009; (Issue 1323)
The FDA has approved degarelix (Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer....
The FDA has approved degarelix (Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer. Abarelix (Plenaxis), the first GnRH antagonist approved by the FDA, was withdrawn from the US market because of immediate hypersensitivity reactions.
Golimumab (Simponi) for Inflammatory Arthritis
The Medical Letter on Drugs and Therapeutics • July 13, 2009; (Issue 1316)
Golimumab (Simponi - Centocor), a fully humanized anti-tumor necrosis factor (TNF)-a antibody, has been approved by the FDA for the treatment of: (1) moderate to severe active rheumatoid arthritis (RA) in...
Golimumab (Simponi - Centocor), a fully humanized anti-tumor necrosis factor (TNF)-a antibody, has been approved by the FDA for the treatment of: (1) moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate; (2) active psoriatic arthritis (PsA) alone or in combination with methotrexate; and (3) active ankylosing spondylitis (AS).
Prostate Cancer Screening
The Medical Letter on Drugs and Therapeutics • November 3, 2008; (Issue 1298)
The US Preventive Services Task Force (USPSTF) has recently concluded that available evidence is insufficient to assess the balance between potential benefits and harms of using the prostate-specific antigen...
The US Preventive Services Task Force (USPSTF) has recently concluded that available evidence is insufficient to assess the balance between potential benefits and harms of using the prostate-specific antigen (PSA) to screen men < 75 years old for prostate cancer and has recommended against screening men > 75 years old.
Finasteride for Prevention of Prostate Cancer
The Medical Letter on Drugs and Therapeutics • June 30, 2008; (Issue 1289)
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to...
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to take finasteride (Proscar, and others) to prevent prostate cancer.
Screening Tests for Cancer
The Medical Letter on Drugs and Therapeutics • September 1, 2005; (Issue 37)
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed.